Telbivudine improves renal function in patients with chronic hepatitis b

Gastroenterology

Volumn 146, Issue 1, 2014, Pages

  Gane, Edward J ^a   Deray, Gilbert ^b   Liaw, Yun Fan ^c   Lim, Seng Gee ^d   Lai, Ching Lung ^e   Rasenack, Jens ^f   Wang, Yuming ^g   Papatheodoridis, George ^h   Di Bisceglie, Adrian ⁱ   Buti, Maria ^j   Samuel, Didier ^k,l,m   Uddin, Alkaz ⁿ   Bosset, Sophie ⁿ   Trylesinski, Aldo ⁿ  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e QUEEN MARY HOSPITAL   (Hong Kong)

^f UNIVERSITY OF FREIBURG   (Germany)

^g THIRD MILITARY MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k HÔPITAL PAUL BROUSSE   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m Universite Paris Sud   (France)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Chronic Hepatitis B; Chronic Renal Disease; Glomerular Filtration Rate; Telbivudine

Indexed keywords

CREATININE; LAMIVUDINE; TELBIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK ASSESSMENT;

EID: 84890633973     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.09.031     Document Type: Article

References (40)

1. B. Combes, J. Shorey, and A. Barrera Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane Lancet 2 1971 234 237
2. K.N. Lai, P.K. Li, and S.F. Lui Membranous nephropathy related to hepatitis B virus in adults N Engl J Med 324 1991 1457 1463
3. G. Appel Viral infections and the kidney: HIV, hepatitis B, and hepatitis C Cleve Clin J Med 74 2007 353 360
4. C.H. Zeng, H.M. Chen, and R.S. Wang Etiology and clinical characteristics of membranous nephropathy in Chinese patients Am J Kidney Dis 52 2008 691 698
5. th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany.
6. S. Mauss, F. Berger, and N. Filmann Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B J Hepatol 55 2011 1235 1240
7. N.B. Ha, R.T. Garcia, and H.N. Trinh Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil Hepatology 50 2009 727 734
8. S. Nair, S. Verma, and P.J. Thuluvath Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation Hepatology 35 2002 1179 1185
9. D.N. Amarapurkar, P. Dhawan, and R.H. Kalro Role of routine estimation of creatinine clearance in patients with liver cirrhosis Indian J Gastroenterol 13 1994 79 82
10. S.U. Kim, K.H. Han, and C.M. Nam Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites J Gastroenterol Hepatol 23 2008 1722 1727
11. R.S. Brown Jr., M. Lombardero, and J.R. Lake Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation Transplantation 62 1996 1788 1793
12. R.J. Fontana Side effects of long-term oral antiviral therapy for hepatitis B Hepatology 49 Suppl 2009 S185 S195
13. Y.J. Kim, H.C. Cho, and D.H. Sinn Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients J Gastroenterol Hepatol 27 2012 306 312
14. I. Mederacke, C. Yurdaydin, and A. Grosshennig Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection J Viral Hepat 19 2012 387 395
15. th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), October 29-November 2, 2010, Boston, MA.
16. R. Gish, M. Clark, and S. Kane Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B Clin Gastroenterol Hepatol 10 2012 941 946
17. th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), October 30-November 3, 2009, Boston, MA.
18. V. Mallet, I. Poizot-Martin, and A. Vallet-Pichard Renal impairment under nucleotide analogues in a monocentric cohort of patients with chronic HBV monoinfection Hepatology 54 2011 1047A
19. Y.F. Liaw, E. Gane, and N. Leung 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
20. C.W. Hsu, Y.C. Chen, and Y.F. Liaw Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from Globe and 015 studies in chronic hepatitis B patients J Hepatol 50 2009 S331 S337
21. J. Jia, J. Hou, and Y. Yin Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B Hepatol Int 3 2009 43 44
22. Y. Wang, S. Thongsawat, and E.J. Gane Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B J Viral Hepat 20 2013 e37 e46
23. H.L. Chan, Y.C. Chen, and E.J. Gane Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis J Viral Hepat 19 2012 732 743
24. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
25. A.S. Levey, J.P. Bosch, and J.B. Lewis A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
26. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
27. O. Gerasimova, D.A. Granov, and F.K. Zherebtsov Efficacy and safety of telbivudine in patients after orthotopic liver transplantation: a single-center clinical experience Hepatol Int 5 2011 129 130
28. A. Perrella, A.G. Lanza, and W. Santaniello Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience Transplant Proc 44 2012 1986 1988
29. D.N. Amarapurkar, and N. Patel Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection Indian J Gastroenterol 2013 Mar 20 [Epub ahead of print]
30. J. Hou, J. Sun, and Q. Xie Virological breakthrough and genotypic resistance in a randomized, controlled study on telbivudine treatment applying roadmap concept in CHB: W76 interim analysis of EFFORT study J Hepatol 56 2012 S203 S204
31. J. Sun, T. Piratvisuth, and D.N. Amarapurkar Consistent renal function improvement with telbivudine treatment in combination with adefovir or tenofovir Hepatology 56 2012 401A
32. T. Piratvisuth, P. Komolmit, and T. Tanwandee 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B PLoS One 8 2013 e54279
33. C.W. James, M.C. Steinhaus, and S. Szabo Tenofovir-related nephrotoxicity: case report and review of the literature Pharmacotherapy 24 2004 415 418
34. A. Tamori, M. Enomoto, and S. Kobayashi Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus J Viral Hepat 17 2010 123 129
35. Y.F. Liaw, M. Raptopoulou-Gigi, and H. Cheinquer Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study Hepatology 54 2011 91 100
36. Y.F. Liaw, I.S. Sheen, and C.M. Lee Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 2011 62 72
37. EASL clinical practice guidelines Management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
38. Uteng M, Mahl A, Beckmann N, et al. Preclinical assessment on renal function and toxicity of chronic hepatitis B (CHB) drugs telbivudine, entecavir, tenofovir and adefovir. Asian Pacific Association for the Study of the Liver (APASL) Liver Week 2013, June 6-10, Singapore.
39. H. Izzedine, V. Launay-Vacher, and G. Deray Antiviral drug-induced nephrotoxicity Am J Kidney Dis 45 2005 804 817
40. H. Izzedine, J.S. Hulot, and E. Villard Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy J Infect Dis 194 2006 1481 1491